Tag Archives: Amgen

Ascletis Doses First Patient in Ph3; Arrowhead ESC 2026 Investor Event; Cytokinetics ACACIA-HCM Primary Results; Amgen Repatha Sub-Analyses; Alnylam Vutrisiran Sub-Analysis; Lilly 52-Week Taltz + Tirzepatide Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Arrowhead Pharmaceuticals, Cytokinetics, Amgen, Alnylam, and Lilly. Below, FENIX provides highlights and insights for the respective news items, including a projected approval timeline for Ph3 oral AOM development.

This content is for Read Less members only.
Already a member? Log in here

AZ/BMS Merger to Challenge CVRM Leaders?; Novo Business Updates; Merck, Pfizer, Amgen, and Arrowhead Q2 ’26 Earnings; Ascletis Initiates Ph3 Oral GLP-1RA Program; Lilly Reta Expanded Access; Corbus CB1 Update

A series of cardiometabolic-related news items has been observed from AZ/BMS, Novo Nordisk, Merck, Pfizer, Amgen, Arrowhead Pharmaceuticals, Ascletis Pharma, Lilly, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items, including insights into how the rumored AZ/BMS merger may impact the future CVRM market.

This content is for Read Less members only.
Already a member? Log in here

AZ/CSPC CVRM Deal; Amgen Initiates New Ph1 T2DM Study; Ascletis Files US INDs; Regeneron Posts New Ph2 Olatorepatide Study; Trinity CGM+ Results; Wegovy MASH MHRA Approval; Adocia/Sanofi M1Pram Agreement Expiration; ViCentra Hybrid Closed Loop Germany Launch

A series of cardiometabolic-related news items has been observed from AstraZeneca/CSPC Pharmaceutical, Amgen, Ascletis Pharma, Regeneron Pharmaceuticals, Trinity Biotech, MHRA, Adocia, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Sirius Posts New Obesity Study; Amgen Expands US Manufacturing Investment; Insulet Initiates T2DM FCL Study

Three cardiometabolic-related news items have been observed: Sirius Therapeutics posted a new Ph1/2 obesity study on CT.gov (view CT.gov record); Amgen expanded its investment in US manufacturing by an additional $300M (view press release); and Insulet initiated its EVOLVE FCL study in T2DM (view press release). Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Thoughts on The TrumpRx Launch: The Future Booking.com of Obesity Drugs?

The White House recently launched TrumpRx.gov (view website), an online platform that allows consumers to search for the lowest available cash-pay prices for their prescription medications (view image below). Importantly, the website itself is not the direct point of purchase for consumers; instead, it is a central hub that informs patients of the available out-of-pocket pricing options before redirecting them to purchase the drug by what appears to be two contrasting pathways (discussed below). Below, FENIX outlines how TrumpRx operates, its potential value creation, and why the platform may disproportionately benefit AOM manufacturers.

This content is for Read Less members only.
Already a member? Log in here